Astellas Pharma Inc.

TSE:4503 Rapport sur les actions

Capitalisation boursière : JP¥3.0t

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Astellas Pharma Gestion

Gestion contrôle des critères 1/4

Astellas Pharma's CEO is Naoki Okamura, appointed in Apr 2023, has a tenure of 1.33 years. total yearly compensation is ¥461.00M, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 0.003% of the company’s shares, worth ¥96.00M. The average tenure of the management team and the board of directors is 4.6 years and 1.2 years respectively.

Informations clés

Naoki Okamura

Directeur général

JP¥461.0m

Rémunération totale

Pourcentage du salaire du PDG29.5%
Durée du mandat du directeur général1.3yrs
Propriété du PDG0.003%
Durée moyenne d'occupation des postes de direction4.6yrs
Durée moyenne du mandat des membres du conseil d'administration1.2yrs

Mises à jour récentes de la gestion

Recent updates

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Aug 20
Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 04
Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 26
Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Jul 11
Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Is Astellas Pharma (TSE:4503) A Risky Investment?

Jun 14
Is Astellas Pharma (TSE:4503) A Risky Investment?

Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear

May 02
Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear

Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 29
Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Feb 29
Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Analyse de la rémunération des PDG

Comment la rémunération de Naoki Okamura a-t-elle évolué par rapport aux bénéfices de Astellas Pharma?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

JP¥22b

Mar 31 2024JP¥461mJP¥136m

JP¥17b

Dec 31 2023n/an/a

JP¥4b

Sep 30 2023n/an/a

JP¥38b

Jun 30 2023n/an/a

JP¥107b

Mar 31 2023JP¥204mJP¥70m

JP¥99b

Dec 31 2022n/an/a

JP¥136b

Sep 30 2022n/an/a

JP¥149b

Jun 30 2022n/an/a

JP¥118b

Mar 31 2022n/an/a

JP¥124b

Dec 31 2021n/an/a

JP¥120b

Sep 30 2021n/an/a

JP¥119b

Jun 30 2021n/an/a

JP¥101b

Mar 31 2021JP¥236mJP¥70m

JP¥121b

Dec 31 2020n/an/a

JP¥138b

Sep 30 2020n/an/a

JP¥140b

Jun 30 2020n/an/a

JP¥187b

Mar 31 2020JP¥232mJP¥53m

JP¥195b

Rémunération vs marché: Naoki's total compensation ($USD3.14M) is above average for companies of similar size in the JP market ($USD1.64M).

Rémunération et revenus: Naoki's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.


PDG

Naoki Okamura (62 yo)

1.3yrs

Titularisation

JP¥461,000,000

Compensation

Mr. Naoki Okamura, BSc, served as Chief Business Officer at Astellas Pharma Inc. since September 2021 until 2022. He served as Executive Vice President at Astellas Pharma Inc. since 2021 until April 1, 202...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Naoki Okamura
President1.3yrsJP¥461.00m0.0032%
¥ 96.0m
Atsushi Kitamura
Senior Executive Officer & CFO1.6yrspas de donnéespas de données
Nobue Yasuda
General Manager of Finance & Accounting Departmentno datapas de donnéespas de données
Yoshitsugu Shitaka
Chief Scientific Officer & Senior Managing Executive Officer3.6yrspas de donnéespas de données
Catherine Levitt
General Counselno datapas de donnéespas de données
Katsuyoshi Sugita
Chief People Officer3.3yrspas de données0.00061%
¥ 18.4m
Stig Ogata
Vice President of Corporate Communications6.3yrspas de donnéespas de données
Tatjana Dragovic
Senior VP and Head of Ethics & Compliance6.4yrspas de donnéespas de données
Nobuaki Tanaka
President of Japan Commercial & Senior Corporate Executive8.2yrspas de donnéespas de données
Jun Kono
Senior Executive Officer & Head of Japan Commercialless than a yearpas de donnéespas de données
Hideki Shima
Chief Manufacturing Officer & Senior Corporate Executive5.6yrspas de donnéespas de données
Leticia Delgado-Herrera
VP and Rx+ M&D Head5.6yrspas de donnéespas de données

4.6yrs

Durée moyenne de l'emploi

Gestion expérimentée: 4503's management team is considered experienced (4.6 years average tenure).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Naoki Okamura
President5.2yrsJP¥461.00m0.0032%
¥ 96.0m
Katsuyoshi Sugita
Chief People Officer1.2yrspas de données0.00061%
¥ 18.4m
Takashi Tanaka
Independent Outside Director3.2yrspas de donnéespas de données
Masahiro Miyazaki
Outside Independent Director1.2yrspas de données0.000060%
¥ 1.8m
Kenji Yasukawa
Chairman of the Board7.2yrsJP¥309.00m0.010%
¥ 301.3m
Tomoko Aramaki
Outside Independent Directorless than a yearpas de donnéespas de données
Eriko Sakurai
Independent Outside Director2.2yrspas de donnéespas de données
Mika Nakayama
Independent Outside Director2.2yrspas de donnéespas de données
Rie Akiyama
Outside Independent Director1.2yrspas de donnéespas de données
Yoichi Ohno
Outside Independent Director1.2yrspas de donnéespas de données
Rika Hirota
Directorless than a yearpas de donnéespas de données

1.2yrs

Durée moyenne de l'emploi

63yo

Âge moyen

Conseil d'administration expérimenté: 4503's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.